TNF Pharmaceuticals (NASDAQ:TNFA) Announces Earnings Results

TNF Pharmaceuticals (NASDAQ:TNFA) issued its quarterly earnings results on Friday. The company reported ($0.66) EPS for the quarter, Zacks reports.

TNF Pharmaceuticals Stock Performance

Shares of TNFA traded up $0.02 during mid-day trading on Friday, hitting $0.28. The company’s stock had a trading volume of 283,110 shares, compared to its average volume of 396,418. TNF Pharmaceuticals has a fifty-two week low of $0.21 and a fifty-two week high of $2.16. The firm has a 50-day moving average price of $0.42 and a 200 day moving average price of $1.02.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.